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Prognostic factors in patients with Rocky Mountain Spotted 
Fever 
Hiram J. Jaramillo-Ramírez,1 Jeremy J. Hernández-Ríos,2 Fátima M. Martínez-González,2 Luz A. Gutiérrez-Bañales,2 Eliot R. García-Valenzuela,2 J. 
Andrés Beltrán-López,2 Jorge L. Peterson,3 Flor M. Yocupicio,3 Rodolfo Ruíz-Luján.4 
Abstract 
Background: Rocky Mountain Spotted Fever (RMSF) is a disease with a high mortality rate, caused by Rickettsia rickettsii, a bacteria transmitted to humans 
by infected ticks. In 2008 there was a Rocky Mountain Spotted Fever (RMSF) outbreak in the city of Mexicali, México, resulting in an increased mortality 
rate amongst the area population. Methods: Case-series study of patients admitted to the General Hospital of Mexicali between 2014 and 2019 with a 
confirmed diagnosis of RMSF. Mortality was compared dividing the population on those ≤20 and younger than ˃21 years of age. Results: A total of 129 
patients’ records during a 5-year period whose diagnosis was RMSF confirmed with PCR were included. Mortality was compared among patients admitted 
who were younger than ≤20 years of age with that among patients who were older than ˃20 years of age (61 versus 68 respectively), the latter being 
higher with an OR 4.2 (p<0.0001). Conclusion: RMSF in hospitalized patients has a high mortality rate in spite of early treatment in all age groups, without 
showing any predominance in gender. However, patients older than 20 years of age had a higher mortality rate than those younger than 20 years, without 
any predominance in gender. 
 




There are various disease-causing agents from the Rickettsia group, in 
North America and México some species prevail like R. rickettsii, R. 
akari, R. prowazekii, R. typhi y R. parkeri, the last one being a common 
infectious agent in the state of Arizona, United States of America (USA). 
and has been identified in ticks located in a city of México, however, 
there aren’t reports of infected patients.1-2 
 
Rocky Mountain Spotted Fever (RMSF) is a disease with a high mortality 
rate, caused by Rickettsia rickettsii, a bacteria transmitted to humans 
by infected ticks.1, 4-5 This disease can be found in North and Central 
America, with a higher prevalence in México, Canada and United States 
of America.6 Ticks are the natural reservoirs of Rickettsia rickettsii, their 
life cycle lasts approximately two to three years. In the fall, adult 
females drop off the host to lay eggs which hatch into larvae and later 
attach to their first host. Then in the summer, larvae abandon the host 
and molt into nymphs.3 During the following spring, nymphs attach to 
the second host, they feed on it and drop off later in the summer. 
Nymphs molt into adults and attach to a third host to feed and mate 
on it. Lastly, females drop off the host in the fall to continue the cycle.14 
 
RMSF was first described in early 1899 by Edward E. Maxey, he 
demonstrated an interest for the disease while reading an article called 
“Some observation on the so-called spotted fever of Idaho”, and 
described it as “A febrile disease, clinically characterized by continuous 
moderately high fever, severe arthritic and muscular pains and 
petechial or purpuric eruption in the skin, appearing first on ankles, 
wrist and forehead”.11, 15  Variation in clinical presentation interferes 
with diagnosis and with it the start of specific treatment, which 
increases mortality. Fever rose up to 38.9° C in 63% of patients during 
the first 3 days, and in 90% of patients during the first week.8 In 49% 
of patients skin lesions appeared during the first 3 days after fever 
developed, rising to 88-90% of patients during the 3rd and 5th day, these 
are representative signs of the disease. In severe cases, gangrene may 
appear in upper and lower extremities, as well as ears and scrotum.4, 
10 The combination of skin lesions by bacteria and vasculitis can result 
in skin necrosis and gangrene that may require amputation.7-8, 12  
 
Diagnosis is usually achieved with indirect immunofluorescence, or 
with high antibody levels.13 Other techniques like DNA amplification 
with polymerase chain reaction (PCR) have very sensitive and specific 
results, however, these techniques aren’t always available in the 
country of México.13 
 
The aim of the study is to demonstrate the benefit of an early treatment 
(initiation of treatment ≤5 days after the beginning of symptoms), to 
identify risk factors that increase mortality rate amongst the population 
of the city of Mexicali, México, and the importance of an accurate 
diagnosis as a prognostic factor. 
 
Methods 
Case series of patients admitted to the General Hospital of Mexicali, a 
city located in northwestern México, between 2014 and 2019 with a 
confirmed diagnosis of Rocky Mountain Spotted Fever. The diagnosis 
was confirmed by polymerase chain reaction (PCR), which was 
processed by the Thermocycler Applied Biosystems 7500 Real-Time PCR 
System with llustraTM puRe Taq Ready-To-GoTM PCR Beads, according 
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to the policies of the Institute of Diagnosis and Epidemiological 
reference.  
 
We searched the patients’ charts for the following variables: Date of 
admission, age, gender, multimorbidities, time between symptom 
onset and the initiation of treatment, animal contact, previous tick 
bites, signs, symptoms, and laboratory tests (Table 1). Delayed 
treatment was defined as the initiation of treatment ≥5 days after the 
beginning of symptoms. 
 
Information was analyzed with MiniTab statistical package version 
19.2.0 and with the aid of Microsoft Office Excel (2018). Spearman’s 
correlation coefficient was used to interpret all data. The study was 




A total of 129 hospitalized patients’ records were included, all 
diagnosed with Rocky Mountain Spotted Fever confirmed by PCR (Table 
1). There were 71 males (55%) and 58 women (45%) with age ranging 
between 1-67 years old, with a mean of 25 years From the patient total, 
58% were diagnosed during summer (April-September), and 42% during 
winter (October-March). Forty-one patients died, from which 51% were 
females, not showing a statistical difference between genders. We 
compared mortality among patients admitted who were ≤ 20 years of 
age with that among patients ˃21 years of age, the latter being higher 
with an Odds Ratio (OR) of 4.2 (95% Confidence Interval [95% CI]: 1.86-
9.78, p=0.0001). One hundred five patients were tested for serum 
electrolytes, 71% developed hyponatremia (<135 mEq/L). Mortality rate 
in patients with hyponatremia was 34%, compared to those who did 
not have hyponatremia for an OR of 1.7 (95% CI 0.6-4.6; p=0.13) not 
statistically significant. 
 
From the 51 patients with delayed treatment, 17 cases were fatal (33%) 
(OR 1.37, 95% CI 0.6-3.11; p=0.2). When comparing the group of patients 
who received delayed treatment against those who received early 
treatment (≤5 days after the onset of symptoms), mortality rate for 
patients who received delayed treatment was 33%, with an OR of 1.37 
(95% CI 0.6-3.11) 
 
We gathered platelet levels from 111 patients, where 99 patients (76%) 
presented with thrombocytopenia below 150,000 cells (OR 6.01, 95% CI 
0.7-48, p=0.02), in comparison to those who did not develop 
thrombocytopenia. 
 
A total of 100 patients presented exanthema, from which 31 died, with 
an OR 0.8 (95% CI, 0.3-2.04; p=0.3) without representing a risk factor for 
mortality. Skin necrosis of the limbs is a known complication, which 
was present in 9 patients from our sample (7%). Six of them died (67%) 
OR 4.6 (95% CI 1.1-20, p<0.02). 
 
Acute kidney injury (considered as a creatinine value > 1.5 mg/dL based 
on the KDIGO criteria for Acute Kidney Injury) is a risk factor associated 
with higher mortality rate (OR 9, 95% CI 3.4-23.5, p <0.001). Neurological 
dysfunction was present in 68 patients (53%), from which 26 (38%) died 
(OR 1.8, 95% CI, 0.88-4; p=0.05). 
 
A higher incidence was recorded during the months of July and 
September, with a total of 42 patients (33%), and a fatal outcome in 12 
of them (28%), in comparison to the rest of the months where the 
incidence was 19-23%. 
 
Discussion 
RMSF has a rising incidence in northwestern regions of México, where 
the weather mainly consists of two seasons, summer (April-September) 
and winter (October-March). Those who did not receive treatment had 
a 30% mortality, which could be reduced to 15% with treatment. 7-8 In 
this study there were 129 patients, all diagnosed with a confirmatory 






Table 1. Characteristics of patients with RMSF † admitted to the General Hospital of Mexicali (n=129) 
 
Demographic Total (%) Fatal Non-fatal % Lethal OR (95%CI) p-value 
Male 71 (55) 20 51 28 Ref  
Female 58 (44.9) 21 37 36 0.69 (0.3-1.4)  
Age Total Fatal Non-fatal % Lethal OR  
<20 years 61 (47.2) 10 51 16 Ref  
>20 years 68 (52.7) 31 37 45 4.27 (1.86-9.78) <0.0001 
Hyponatremia 68 (71.4) 23 45 34 1.7 (0.6-4.6)  
Thrombocytopenia 99 (76.7) 35 64 35 6.01 (0.7-48)  
Delayed treatment 
(>5 days) 51 (39.5) 17 34 33 1.37 (0.6-3.11)  
Rash 100 (77.5) 31 69 31 1.1 (0.35-2.04)  
Necrosis 9 (6.97) 6 3 66 4.8 (1.1-20) <0.02 
Neurological dysfunction 68 (52.7) 26 42 38 1.8 (0.88-4)  
Elevated creatinine 52 (40.3) 29 23 55 9 (3.4-23.5) <0.001 
Cases per month Total Fatal Non-fatal % Lethal   
Jan-Mar 30 (23.2) 9 21 30   
Apr-Jun 33 (25.5) 12 21 36   
Jul-Sep 42 (32.5) 12 30 28   
Oct-Dic 24 (18.6) 8 16 33   
 




Jaramillo-Ramírez HJ, et al. Prognostic Factors in Patients with Rocky Mountain Spotted Fever
 
 
Int J Med Students   •   2020  |  May-Aug  |  Vol  8  |  Issue 2 
                             DOI 10.5195/ijms.2020.459  |  ijms.info The International Journal of Medical Students 109
 
 
There was a 32% mortality rate, twice as much as those reported by 
previous studies in México.3, 8 This high mortality rate in treated 
patients can be explained because patients that were hospitalized were 
more severe than those who received ambulatory treatment. Treatment 
initiation delay is not related with a high mortality rate, unlike the 2016 
study. 3 Mortality is also related to the presence of skin necrosis of the 
limbs with an OR 4.6, a variant not considered in the previous study. 3 
RMSF in hospitalized patients has a high mortality rate in spite of early 
treatment in all age groups, without showing any predominance in 
gender 9. However, patients older than 20 years of age had a higher 
mortality rate than those younger than 20 years, without any 
predominance in gender. Acute kidney injury, skin necrosis of the 
limbs, and age older than 20 years were predictors of mortality. 
Thrombocytopenia was also a risk factor for higher mortality rate, yet, 
only one patient without thrombocytopenia died. Such a small sample 
makes it almost impossible to define its risk accurately. 
 
Regarding treatment, tetracyclines have been the only accepted 
treatment for RMSF for many years, however, the medical community 
is in need of alternative solutions just as effective as doxycycline, but 
these may require future research.7 
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